The Hindu·3 min read·medium
Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit
N
N. Ravi Kumar
✦AI Summary
Dr. Reddy’s Laboratories has delayed commercial supplies of its semaglutide drug due to quality issues with the active pharmaceutical ingredient. The company's shares fell over 5% following the announcement, though it maintains that patient safety remains unaffected.
Dr. Reddy’s Laboratories has decided to delay commercial supplies of semaglutide due to an issue associated with the active pharmaceutical ingredient (API) used in the drug, an announcement on Thursday (July 9, 2026) that saw the generic drugmaker’s shares plunge.
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in